HUP9903876A2 - Compounds and methods for diagnosis of tuberculosis - Google Patents
Compounds and methods for diagnosis of tuberculosisInfo
- Publication number
- HUP9903876A2 HUP9903876A2 HU9903876A HUP9903876A HUP9903876A2 HU P9903876 A2 HUP9903876 A2 HU P9903876A2 HU 9903876 A HU9903876 A HU 9903876A HU P9903876 A HUP9903876 A HU P9903876A HU P9903876 A2 HUP9903876 A2 HU P9903876A2
- Authority
- HU
- Hungary
- Prior art keywords
- ala
- pro
- gly
- thr
- val
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 201000008827 tuberculosis Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 12
- 239000000427 antigen Substances 0.000 abstract 9
- 102000036639 antigens Human genes 0.000 abstract 9
- 108091007433 antigens Proteins 0.000 abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 238000012986 modification Methods 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 108091093088 Amplicon Proteins 0.000 abstract 1
- 102000053602 DNA Human genes 0.000 abstract 1
- 239000003155 DNA primer Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Abstract
A new polypeptide (A) comprises an antigenic portion of a soluble Mycobacterium tuberculosis (MT) antigen, or a variant of the antigen that differs only in conservative substitutions and/or modifications, the antigen has an N-terminal sequence selected from: (a) Asp-Pro-Val-Asp-Ala-Val-Ile-Asn-Thr-Thr-Cys-Asn-Tyr-Gly-Gln-Val-Val-Ala-Ala-Leu (I); (b) Ala-Val-Glu-Ser-Gly-Met-Leu-Ala-Leu-Gly-Thr-Pro-Ala-Pro-Ser (II); (c) Ala-Ala-Met-Lys-Pro-Arg-Thr-Gly-Asp-Gly-Pro-Leu-Glu-Ala-Ala-Lys-Glu-Gly-Arg (III); (d) Tyr-Tyr-Trp-Cys-Pro-Gly-Gln-Pro-Phe-Asp-Pro-Ala-Trp-Gly-Pro (IV); (e) Asp-Ile-Gly-Ser-Glu-Ser-Thr-Glu-Asp-Gln-Gln-Xaa-Ala-Val (V); (f) Ala-Glu-Glu-Ser-Ile-Ser-Thr-Xaa-Glu-Xaa-Ile-Val-Pro (VI); (g) Asp-Pro-Glu-Pro-Ala-Pro-Pro-Val-Pro-Thr-Thr-Ala-Ala-Ser-Pro-Pro-Ser (VII); (h) Ala-Pro-Lys-Thr-Tyr-Xaa-Glu-Glu-Leu-Lys-Gly-Thr-Asp-Thr-Gly; (VIII); (i) Asp-Pro-Apa-Ser-Ala-Pro-Asp-Val-Pro-Thr-Ala-Ala-Gln-Leu-Thr-Ser-Leu-Leu-Asn-Ser-Leu-Ala-Asp-Pro-Asn-Val-Ser-Phe-Ala-Asn (I X); (j) Ala-Pr o-Glu-Ser-Gly-Ala-Gly-Leu-Gly-Leu-Gly-Gly-Thr-Val-Gln-Ala-Gly (X); where Xaa may be any amino acid. Also claimed are: (1) a polypeptide comprising an immunogenic portion of an MT antigen or a variant of the antigen that differs only in conservative substitutions and/or modifications, where the antigen has an N-terminal sequence selected from: (a) Asp-Pro-Pro-Asp-Pro-His-Gln-Xaa-Asp-Met-Thr-Lys-Gly-Tyr-Tyr-Pro-Gly-Gly-Arg-Arg-Xaa-Phe (XI); and (b) Xaa-Tyr-Ile-Ala-Tyr-Xaa-Thr-Thr-Ala Gly-Ile-Val-Pro-Gly-Lys-Ile-Asn-Val-His-Leu-Val (XII); (2) a polypeptide comprising an antigenic portion of a soluble MT antigen, or a variant of the antigen that differs only in conservative substitutions and/or modifications, where the antigen comprises an amino acid sequence encoded by DNA of one of the 766, 752, 447, 604, 633, 1362, 1458, 862, 622, 1771, 1058, 913, 1872, 1482, 876, 1021, 321, 373, 352, 726, 580, 999, 507 and 500 bp sequences given in the specification, or the complements of the sequences, or DNA sequences that hybridise to these sequences or a complement under moderately stringent conditions; (3) a polypeptide as in (2) except that it is encoded by one of the 272, 317, 182, 308, 267, 1539, 851, 254, 1227, 181, 290, 34, 155, 53, 41, 132, 702, 298, 1058, 327, 170, 127, 81, 149, 355, 999, 882, 815, 264, 1171, 227, 304, 1439, 329, 80, 392, 535, 690, 407, 468, 219, 494, 220, 388, 400, 538, 239, 985, 2138 and 2367 bp sequences given in the specification, the complements of the sequences, and DNA sequences that hybridise to a these sequences or a complement under moderately stringent conditions; (4) a DNA molecule (I) comprising a nucleotide sequence encoding a polypeptide as in (A) or as described in (1), (2) or (3); (5) an expression vector comprising (I); (5) a host cell transformed with an expression vector as in (5); (6) a method for detecting M. tuberculosis comprising contacting a biological sample with a peptide (A) or as described in (1), (2) or (3) and detecting antibodies that bind to these peptides; (7) a method as in (6) except that the peptide is one of a 15 or 15 aa sequence given in the specification; (8) a method as in (6) except that the peptide is encoded by one of the 813, 1200, 1155, 1152, 136, 1777, 324, 1338, 321, 492, 536, 2072,1923, 1055, 359, 350, 811, 966 and 2852 sequences given in the specification. (9) a method for detecting M. tuberculosis comprises using PCR and two oligonucleotide primers specific to the (I) or the sequences described in (6) to generate a detectible amplicon. (10) a method for detecting M. tuberculosis comprises using probes that hybridise specifically to the DNA sequences as described in (6);(11) a method for detecting M. tuberculosis comprises: (a) contacting a sample with a binding agent that can bind (A) or a peptide as described in (1), (2), (3) or (6), or as described in the two 15 aa sequences given in the specification; and (b) detecting the bound peptide; (12) a polyclonal antibody that binds to (A) or a peptide as in (1), (2) or (3); (13) a fusion protein comprising (A)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903876A HUP9903876A3 (en) | 1997-10-07 | 1997-10-07 | Compounds and methods for diagnosis of tuberculosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903876A HUP9903876A3 (en) | 1997-10-07 | 1997-10-07 | Compounds and methods for diagnosis of tuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9903876A2 true HUP9903876A2 (en) | 2000-02-28 |
| HUP9903876A3 HUP9903876A3 (en) | 2001-03-28 |
Family
ID=89999840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9903876A HUP9903876A3 (en) | 1997-10-07 | 1997-10-07 | Compounds and methods for diagnosis of tuberculosis |
Country Status (1)
| Country | Link |
|---|---|
| HU (1) | HUP9903876A3 (en) |
-
1997
- 1997-10-07 HU HU9903876A patent/HUP9903876A3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9903876A3 (en) | 2001-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE420180T1 (en) | COMPOUNDS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS AND METHODS OF USE THEREOF | |
| Franken et al. | Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent | |
| EP0784059A4 (en) | Antigenic polypeptide of chlamydia pneumoniae | |
| HK1222415A1 (en) | Circovirus sequence associated with porcine wasting disease (pwd) (pwd) | |
| CA2370493A1 (en) | Peptides and assays for the diagnosis of lyme disease and compositions useful for the prevention thereof | |
| Hogg et al. | Amino acid sequence of the L-arabinose-binding protein from Escherichia coli B/r. | |
| KR950032283A (en) | Melanoma-associated antigenic polypeptide, epitopes thereof and vaccines against melanoma | |
| JP2004512022A5 (en) | ||
| JP2004512824A5 (en) | ||
| MX9606463A (en) | Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections. | |
| RU97100934A (en) | NUCLEOTIC SEQUENCE OF PESTIVIRUS STRAINS, POLYPEPTIDES CODED BY THESE SEQUENCE, AND THEIR USE FOR DIAGNOSTICS AND PREVENTION OF PESTIVIRUS INFECTIONS | |
| Maier et al. | Strep-tag II affinity purification: an approach to study intermediates of metalloenzyme biosynthesis | |
| CA2219876A1 (en) | Stable variant hk2 polypeptide | |
| JP2002517193A5 (en) | ||
| CA2287571A1 (en) | Reagents and methods useful for detecting diseases of the prostate | |
| JP2002512005A5 (en) | ||
| CA2232237A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
| JP2005535287A5 (en) | ||
| HUP9903876A2 (en) | Compounds and methods for diagnosis of tuberculosis | |
| CA2466474A1 (en) | Compositions comprising spa-1, spa-2 and spa-3, polypeptides and related uses | |
| US5169940A (en) | Nucleotide sequences of protein MTP40 of M. tuberculosis | |
| Eldin et al. | Expression of human β-myosin heavy chain fragments in Escherichia coli; localization of actin interfaces on cardiac myosin | |
| JP2003532369A5 (en) | ||
| CA2370519A1 (en) | Nucleic acids encoding a mutt domain-containing polypeptide | |
| WO2000063383A1 (en) | IgA BINDING POLYPEPTIDE |